Aclaris Therapeutics, Inc. (ACRS) Gross profit 2017–2025
Aclaris Therapeutics, Inc. (ACRS) annual gross profit history from SEC filings — each fiscal year as reported.
$5.7MFY2025 · since FY2017: $476,000 → $5.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $5.7M | -64.0% |
| FY2024 | $15.9M | -42.8% |
| FY2023 | $27.8M | +8.2% |
| FY2022 | $25.7M | +1156.3% |
| FY2021 | $2.0M | +51.8% |
| FY2020 | $1.3M | +684.3% |
| FY2019 | $172,000 | -94.7% |
| FY2018 | $3.2M | +580.9% |
| FY2017 | $476,000 | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ACRS financial trends
ACRS RevenueACRS Net incomeACRS Net marginACRS Gross marginACRS Operating incomeACRS Operating marginACRS Operating cash flowACRS Free cash flowACRS Capital expendituresACRS Return on equityACRS Stock buybacksACRS Dividends paidACRS Total assetsACRS Total liabilitiesACRS Shareholders’ equityACRS overview →